These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 17653083

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2007 May 15; 67(10):4981-8. PubMed ID: 17510429
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor].
    Fu YB, Sun QX, Meng FY, Xie J, Zhou GB.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 12; 86(34):2413-6. PubMed ID: 17156654
    [Abstract] [Full Text] [Related]

  • 11. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
    Lauricella M, Emanuele S, D'Anneo A, Calvaruso G, Vassallo B, Carlisi D, Portanova P, Vento R, Tesoriere G.
    Apoptosis; 2006 Apr 12; 11(4):607-25. PubMed ID: 16528474
    [Abstract] [Full Text] [Related]

  • 12. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jäck HM, Voll RE.
    Cancer Res; 2007 Feb 15; 67(4):1783-92. PubMed ID: 17308121
    [Abstract] [Full Text] [Related]

  • 13. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E, Alvarez-Fernández S, Maiso P, Martín-Sánchez J, Vidriales MB, Garayoa M, Ocio EM, Montero JC, Pandiella A, San Miguel JF.
    Haematologica; 2008 Jan 15; 93(1):57-66. PubMed ID: 18166786
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
    Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, Rizzo P, Miele L, Nickoloff BJ.
    Cancer Res; 2005 Jul 15; 65(14):6282-93. PubMed ID: 16024630
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA, Sanchez E, Steinberg J, Shalitin D, Li ZW, Chen H, Berenson JR.
    Eur J Haematol; 2010 Mar 15; 84(3):201-11. PubMed ID: 19929977
    [Abstract] [Full Text] [Related]

  • 18. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
    Bosman MC, Schuringa JJ, Quax WJ, Vellenga E.
    Exp Hematol; 2013 Jun 15; 41(6):530-538.e1. PubMed ID: 23416210
    [Abstract] [Full Text] [Related]

  • 19. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.
    Eur J Haematol; 2008 Feb 15; 80(2):133-42. PubMed ID: 18005386
    [Abstract] [Full Text] [Related]

  • 20. Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.
    Fan F, Tonon G, Bashari MH, Vallet S, Antonini E, Goldschmidt H, Schulze-Bergkamen H, Opferman JT, Sattler M, Anderson KC, Jäger D, Podar K.
    Cancer Lett; 2014 Feb 28; 343(2):286-94. PubMed ID: 24120758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.